Overcoming resistance to immunotherapy in NSCLC?
Understanding the evolution of immunotherapy resistance holds the key to developing novel strategies in NSCLC
Can the benefits of lung cancer screening be extended to never-smokers?
Recent data provide further evidence that non-risk-based screening can improve survival if biomarkers can be identified to target screening to those at the highest risk
A multimodal next-generation approach for early detection and risk stratification in lung cancer
Combining the optimisation of clinical pathways with tumour molecular insights enables more accurate and personalised cancer care
From bispecific to multispecific antibodies: a highly promising field
Development of therapies modulating two or more targets is increasing rapidly despite facing a number of hurdles
Redesigning oncology clinical trials with agentic AI
Semi-autonomous and autonomous foundation models are helping cancer research and anticancer drug development
The challenge of undifferentiated sarcomas
Recent studies have improved current understanding of clinical variability and molecular diversity of this subgroup, but many questions remain
Sex and gender are key for precision oncology and benefit all patients
Several misconceptions around sex- and gender-sensitive medicine still limit its application in cancer research and care
The power of dual-layer genomics in precision oncology
Integrating DNA and RNA profiling is a promising approach to advance cancer characterisation and guide clinical decision-making
Shaping the use of AI in oncology
ESMO plays a central role in developing long-lasting recommendations for a safe and effective use of artificial intelligence supporting oncology stakeholders
Artificial intelligence is expediting the development of therapeutic immunotherapies
AI-driven approaches can help to design minibinders, which may bring new T-cell receptor-based therapies closer to the clinic